Human C-reactive protein and the metabolic syndrome

Current Opinion in Lipidology

Volumn 20, Issue 3, 2009, Pages 182-189

  Devaraj, Sridevi ^a,b   Singh, Uma ^a,b   Jialal, Ishwarlal ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

C reactive protein; Inflammation; Metabolic syndrome; Vascular cells

Indexed keywords

C REACTIVE PROTEIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW;

ANIMALS; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION; INSULIN; METABOLIC SYNDROME X; RISK; SIGNAL TRANSDUCTION;

EID: 67049099210     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32832ac03e     Document Type: Review

References (91)

1. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005; 25:391-406.
2. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:1415-1428.
3. Haffner S, Cassells HB. Metabolic syndrome: a new risk factor of coronary heart disease? Diabetes Obes Metab 2003; 5:359-370.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
5. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28:2745-2749.
6. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288:2709-2716.
7. Alexander CM, Landsman PB, Teutsch SM, Haffner SM, Third National Health and Nutrition Examination Survey (NHANES III). National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52:1210-1214.
8. Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am 2004; 33:431-453.
9. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the 'metabolic syndrome1 and incidence of type 2 diabetes. Diabetes 2002; 51:3120-3127.
10. Freeman D, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103:357-362.
11. Assmann G, Nofer JR, Schulte H. Cardiovascular risk assessment in metabolic syndrome: view from PROCAM. Endocrinol Metab Clin North Am 2004; 33:377-392.
12. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
13. Ridker PM, Glynn PJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97:2007-2011.
14. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107:391-397.
15. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phos-pholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005; 165:2479-2484.
16. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622.
17. Koenig W, Khuseyinova N, Baumert J, Meisinger C. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984-1998. Clin Chem 2008; 54:335-342.
18. Eiriksdottir G, Aspelund T, Bjarnadottir K, et al. Apolipoprotein E genotype and statins affect CRP levels through independent and different mechanisms: AGES-Reykjavik Study. Atherosclerosis 2006; 186:222-224.
19. Yudkin JS, Juhan-Vague I, Hawe E, et al., The HIFMECH Study group. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 2004; 53:852-857.
20. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102:42-47.
21. Vu JD, Vu JB, Pio JR, et al. Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus, and preexisting cardiovascular disease. Am J Cardiol 2005; 96:655-658.
22. Devaraj S, Swarbrick MM, Singh U, et al. CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol 2008; 129:815-822. Compared with matched controls, this study shows that CRP is equivalent to adiponectin, its oligomers, in predicting the MetS.
23. Sugiura K, Tamakoshi K, Yatsuya H, et al. Contribution of adipocytokines to low-grade inflammatory state as expressed by circulating C-reactive protein in Japanese men: comparison of leptin and adiponectin. Int J Cardiol 2008; 130:159-164.
24. Ridker PM, Pare G, Parker A, et al. Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet 2008;82:1185-1192.
25. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109:2818-2825.
26. Freeman DJ, Norrie J, Caslake MJ, et al., West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51:1596-1600.
27. Pischon T, Hu FB, Rexrode KM, et al. Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis 2008; 197:392-399.
28. Takeno M, Yasuda S, Otsuka Y, et al. Impact of metabolic syndrome on the long-term survival of patients with acute myocardial infarction: potential association with C-reactive protein. Circ J 2008; 72:415-419.
29. Gotto AM Jr. Role of C-reactive protein in coronary risk reduction: focus on primary prevention. Am J Cardiol 2007; 99:718-725.
30. de Ferranti SD, Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol 2007; 16:14-21.
31. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356-359.
32. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006; 145:21-29.
33. Jager A, van Hinsbergh VW, Kostense PJ, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vase Biol 1999; 19:3071-3078.
34. Festa A, D'Agostino R Jr, Tracy RP, et al., Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51:1131-1137.
35. Meier-Ewert HK, Ridker PM, Rifai N, et al. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 2001; 47:426-430.
36. Ockene IS, Matthews CE, Rifai N, et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001; 47:444-450.
37. Xu J W, Morita I, Ikeda K, et al. C-reactive protein suppresses insulin signaling in endothelial cells: role of spleen tyrosine kinase. Mol Endocrinol 2007; 21:564-573.
38. D'Alessandris C, Lauro R, Presta I, et al. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser 612 in L6 myocytes, thereby impairing the insulin signaling pathway that promotes glucose transport. Diabetologia 2007; 50:840-849.
39. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 2006; 113:2135-2150.
40. Mauger JF, Levesque J, Paradis ME, et al. Intravascular kinetics of C-reactive protein and their relationships with features of the metabolic syndrome. J Clin Endocrinol Metab 2008; 93:3158-6443. This study shows that the production rate of CRP is the main determinant of CRP levels and is significantly associated with features of MetS as well as adipose-derived cytokines, IL-6, and adiponectin.
41. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107:671-674.
42. Al-Qaisi M, Kharbanda RK, Mittal TK, et al. Measurement of endothelial function and its clinical utility for cardiovascular risk. Vase Health Risk Manag 2008; 4:647-652.
43. Lamon BD, Hajjar DP. Inflammation at the molecular interface of atherogen-esis: an anthropological journey. Am J Pathol 2008; 173:1253-1264.
44. Bakker W, Eringa EC, Sipkema P, et al. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Res 2009;335:165-189.
45. Corretti MC, Anderson TJ, Benjamin EJ, et al. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothe-lial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39:257-265.
46. Vita JA, Keaney JF Jr. Endothelial function: a barometer for cardiovascular risk? Circulation 2002; 106:640-642.
47. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 2003; 11:1278-1289.
48. Shankar SS, Steinberg HO. Obesity and endothelial dysfunction. Semin Vase Med 2005; 5:56-64.
49. Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003; 92:10J-17J.
50. Suzuki T, Hirata K, Elkind MS, et al. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Northern Manhattan Study (NOMAs). Am Heart J 2008; 156:405-410.
51. Hamburg NM, Larson MG, Vita JA, et al. Metabolic syndrome, insulin resistance, and brachial artery vasodilator function in Framingham offspring participants without clinical evidence of cardiovascular disease. Am J Cardiol 2008; 101:82-88.
52. Melikian N, Chowienczyk P, MacCarthy PA, et al. Determinants of endothelial function in asymptomatic subjects with and without the metabolic syndrome. Atherosclerosis 2008; 197:375-382.
53. Rodriguez CJ, Miyake Y, Grahame-Clarke C, et al. Relation of plasma glucose and endothelial function in a population-based multiethnic sample of subjects without diabetes mellitus. Am J Cardiol 2005; 96:1273-1277.
54. Brook RD, Bard RL, Rubenfire M, et al. Usefulness of visceral obesity (waist/ hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol 2001; 88:1264-1269.
55. Wheatcroft SB, Shah AM, Li JM, et al. Preserved glucoregulation but attenuation of the vascular actions of insulin in mice heterozygous for knockout of the insulin receptor. Diabetes 2004; 53:2645-2652.
56. Steinberg HO, Chaker H, Learning R, et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97:2601-2610.
57. Teoh H, Quan A, Lovren F, et al. Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis 2008; 201:318-325.
58. Grad E, Golomb M, Mor-Yosef I, et al. Transgenic expression of human C-reactive protein suppresses endothelial nitric oxide synthase expression and bioactivity after vascular injury. Am J Physiol Heart Circ Physiol 2007; 293:H489-H495.
59. Venugopal SK, Devaraj S, Jialal I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 2003; 108:1676-1678.
60. Schwartz R, Osborne-Lawrence S, Hahner L, et al. C-reactive protein down-regulates endothelial NO synthase and attenuates reendothelialization in vivo in mice. Circ Res 2007; 100:1452-1459.
61. Fichtlscherer S, Breuer S, Schächinger V, et al. C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Eur Heart J 2004; 25:1412-1428.
62. Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102:1000-1006.
63. Cleland SJ, Sattar N, Petrie JR, et al. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci 2000; 98:531-535.
64. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106:1439-1441.
65. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106:913-919.
66. Singh U, Devaraj S, Vasquez-Vivar J, Jialal I. C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol 2007;43:780-791. An important study that describes mechanisms by which CRP increases oxidative stress, resulting in uncoupling of eNOS and reduced eNOS bioactivity, possibly explaining its role in causing endothelial dysfunction.
67. Guan H, Wang P, Rutai H, et al. Adeno-associated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in rats. Clin Chem 2009; 55:274-284. An in-vivo demonstration that administration of CRP results in endothelial dysfunction and hypertension.
68. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107:398-404.
69. Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vase Biol 2005; 25:2216-2221.
70. Nakakuki T, Ito M, Iwasaki H, et al. Rho/Rho-kinase pathway contributes to C-reactive protein-induced plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vase Biol 2005; 25:2088-2093.
71. Cermak J, Key NS, Bach RR, et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-520.
72. Devaraj S, Dasu MR, Singh U, et al. C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis 2009; 203:67-74.
73. Han KH, Hong KH, Park JH, et al. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004; 109:2566-2571.
74. Williams TN, Zhang CX, Game BA, et al. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc[gamma]RII and extracellular signal-regulated kinase pathway: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol 2004; 24:61-66.
75. Woollard KJ, Fisch C, Newby R, et al. C-reactive protein mediates CD11b expression in monocytes through the nonreceptor tyrosine kinase, Syk, and calcium mobilization but not through cytosolic peroxides. Inflamm Res 2005; 54:485-492.
76. Chang MK, Binder CJ, Torzewski M, et al. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 2002; 99:13043-13048.
77. Wang X, Liao D, Bharadwaj U, et al. C-reactive protein inhibits cholesterol efflux from human macrophage-derived foam cells. Arterioscler Thromb Vase Biol 2008; 28:519-526.
78. Singh U, Dasu MR, Yancey PG, et al. Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res 2008; 49:1015-1023. In this study, authors demonstrate in vivo that CRP induces oxidative stress and promotes cholesterol ester accumulation and foam cell formation.
79. Singh U, Devaraj S, Jialal I. C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes. Clin Chem 2009; 55: 361-364.
80. Esposito K, Pontillo A, Giugliano F, et al. Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab 2003;88:1055-1058.
81. Singh U, Devaraj S, Dasu MR, et al. C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Arterioscler Thromb Vase Biol 2006; 26: 2469-2475.
82. Keaney JF Jr, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003; 23:434-439.
83. Fortuño A, San José G, Moreno MU, et al. Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome. Diabetes 2006; 55:209-215.
84. Kobayashi S, Inoue N, Ohashi Y, et al. Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of CRP. Arterioscler Thromb Vase Biol 2003; 23:1398-1404.
85. Ehara S, Ueda M, Naruko T. Elevated levels of oxidized low-density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001; 103:1955-1960.
86. Holvoet P, Kritchevsky SB, Tracy RP, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well functioning elderly people in the health, aging, and body composition cohort. Diabetes 2004; 53:1068-1073.
87. Diamant M, Nieuwland R, Pablo RF, et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106: 2442-2447.
88. Ridker PM, Danielson E, Fonseca F, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207. A pivotal primary prevention trial with rosuvastatin showing significant 37% reduction in CVEs. Although rosuvastatin reduced LDL cholesterol by 50%, the reduction in CVEs in JUPITER was almost twice that predicted based on LDL-cholesterol reduction, and CRP levels were significantly reduced by 37%. Most importantly, in those with no risk factors except a high CRP, there was an equivalent benefit supporting the hypothesis that CRP may mediate atherothrombosis.
89. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066-1071.
90. Ghanim H, Aljada A, Hofmeyer D, et al. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004; 110:1564-1571.
91. Devaraj S, Chan E, Jialal I. Direct demonstration of an anti-inflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 2006; 91:4489-4496.